About LEAD Therapeutics
LEAD Therapeutics was a Healthcare company based in San Bruno (United States) founded in 2006, and was acquired by BioMarin Pharmaceutical in February 2010. Drug discovery company developing therapeutics for cancer and infectious diseases treatment. It operates on a B2B model. LEAD Therapeutics has raised $20 million across 2 funding rounds from investors including BioMarin Pharmaceutical, ProQuest Investments and Mustang Ventures. The company is recorded as dissolved. Its focus areas include Biotechnology, Drug Discovery and Therapeutics Development. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
LEAD Therapeutics drug discovery company developing therapeutics for cancer and infectious diseases treatment, focusing on providing healthcare solutions, advancing biotech innovations, drug discovery, and therapeutics development. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.
- Headquarters San Bruno, United States
- Stage Acquired
- SectorsHealthcare
- Website leadtherapeutics.com
- Acquired by BioMarin Pharmaceutical (Feb 2010)
- Total Equity Funding$20M (USD)
in 2 rounds
- Latest Funding Round$3M (USD), Series A
Jun 2009
- InvestorsBioMarin Pharmaceutical
& 3 more
- Acquired byBioMarin Pharmaceutical
(Feb 2010)
Funding Insights of LEAD Therapeutics
LEAD Therapeutics has successfully raised a total of $20M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3 million completed in June 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20M
- Total Rounds 2
- Last Round Series A — $3M
- First Round $17M
(Nov 2007)
- Investors Count 3
All 2 funding rounds of LEAD Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2009 | $3M | Series A | – | – | – |
| Nov 2007 | $17M | Series A | – | ProQuest Investments, Pappas Capital |
4 investors in total: 4 institutional.
Investors in LEAD Therapeutics
LEAD Therapeutics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include BioMarin Pharmaceutical, ProQuest Investments and Mustang Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| proquestvc.com | ||||
| mustangvc.com | ||||
VC firm focusing on life science sector | pappas-capital.com | Durham, United States | ||
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. | 1997 | biomarin.com | San Rafael, United States |
Investor details for LEAD Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of LEAD Therapeutics
4 dated milestones of LEAD Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded LEAD Therapeutics is founded.
- Funding First funding round of $17.0M.
- Funding Latest funding round, Series A, of $3.0M.
- Exit Acquired by BioMarin Pharmaceutical.
Competitors of LEAD Therapeutics
LEAD Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of LEAD Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as LEAD Therapeutics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lead Therapeutics
Complete news archive for LEAD Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LEAD Therapeutics
LEAD Therapeutics was founded in 2006 and raised its 1st funding round 1 year after it was founded.
LEAD Therapeutics is headquartered in San Bruno, United States. It is registered at San Bruno, California, United States.
LEAD Therapeutics is a funded company, having raised a total of $20M across 2 funding rounds to date. The company's 1st funding round was a Series A of $17M, raised on Nov 2007.
LEAD Therapeutics drug discovery company developing therapeutics for cancer and infectious diseases treatment, focusing on providing healthcare solutions, advancing biotech innovations, drug discovery, and therapeutics development. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.
LEAD Therapeutics's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
LEAD Therapeutics has 4 investors. Key investors include BioMarin Pharmaceutical, ProQuest Investments, Mustang Ventures, and Pappas Capital.
Yes. LEAD Therapeutics was acquired by BioMarin Pharmaceutical in February 2010.